Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1 (previously presented): A method for inducing cell death in a myeloma cancer cell, comprising contacting said myeloma cancer cell with an isocoumarin derivative of the formula:



and further contacting said myeloma cancer cell with a glucocorticoid, wherein the dose of said isocoumarin derivative when combined with the dose of said glucocorticoid is effective to induce cell death in said myeloma cancer cell.

2 (previously amended): The method of claim 2, wherein said inducing cell death comprises inducing apoptosis.

3 (canceled).

4 (currently amended): The method of claim [[4]] 2, wherein said glucocorticoid is dexamethasone or prednisone.

5 (previously presented): The method of claim 1, further comprising contacting said myeloma cancer cell with one or more other chemotherapeutic agents.

6 (original) The method of claim 5, wherein said one or more other chemotherapeutic agents is or are selected from the group consisting of vincristine, doxorubicin, cyclophosphamide, etopside, cisplatin, melphalan, mitoxantrone, BCNU, idarubicin, procarbazine, and cytoxan.

7 (previously presented): A method for inhibiting the proliferation of a myeloma cancer cell, comprising contacting said myeloma cancer with an isocoumarin derivative of the formula:



and further contacting said myeloma cancer cell with a glucocorticoid, wherein the dose of said isocoumarin derivative when combined with the dose of said glucocorticoid is effective to inhibit the proliferation of said myeloma cancer cell.

8 (cancelled)

9 (currently amended) The method of claim [[8]] 7, wherein said glucocorticoid is dexamethasone or prednisone.

10 (previously presented): The method of claim 7, further comprising contacting said myeloma cancer cell with one or more other chemotherapeutic agents.

11 (original) The method of claim 10, wherein said one or more other chemotherapeutic agents is or are selected from the group consisting of vincristine, doxorubicin, cyclophosphamide, etopside, cisplatin, melphalan, mitoxantrone, BCNU, idarubicin, procarbazine, and cytoxan.

12 (original) A method for treating multiple myeloma in a human patient, comprising administering an isocoumarin derivative of the formula:



and administering a glucocorticoid as a second treatment modality, wherein the administration of said isocoumarin derivative when combined with the administration of said glucocorticoid, is effective to treat said multiple myeloma.

13 (original) The method of claim 12, wherein said glucocorticoid is dexamethasone or prednisone.

14 (original) A method for treating multiple myeloma in a human patient, comprising administering an isocoumarin derivative of the formula:



and administering a glucocorticoid as a second treatment modality and administering one or more other chemotherapeutic agents as further treatment modalities, wherein the administration of said isocoumarin derivative when combined with the administration said glucocorticoid and administration of said one or more other chemotherapeutic agents is effective to treat said multiple myeloma.

15 (original) The method of claim 14, wherein said glucocorticoid is dexamethasone.

16 (original) The method of claim 15, wherein said administration of one or more other chemotherapeutic agents is the administration of vincristine as a third treatment modality and the administration of doxorubicin as a fourth treatment modality.

17 (original) The method of claim 14, wherein said one or more other chemotherapeutic agents is or are selected from the group consisting of vincristine, doxorubicin, cyclophosphamide, etopside, cisplatin, melphalan, BCNU and idarubicin.

18 (original) The method of claim 14, wherein said glucocorticoid is prednisone.

19 (original) The method of claim 18, wherein said administration of one or more other chemotherapeutic agents is:
(a) the administration of melphalan as a third treatment modality;
(b) the administration of cyclophosphamide as a third treatment modality; or
(c) the administration of vincristine as a third treatment modality, BCNU as a fourth treatment modality, melphalan as a fifth treatment modality and cyclophosphamide as a sixth treatment modality.

20 (original) The method of claim 18, wherein said one or more chemotherapeutic agents is or are selected from the group consisting of melphalan, mitoxantrone, cyclophosphamide, vincristine, procarbazine, cytoxan, BCNU and doxorubicin.

I. Status of the Claims

Claims 1, 2, 4-7, 9-20 remain in this application. Claims 4 and 9 have been amended.

II. Rejections under 35 U.S.C. § 112, 2nd Paragraph

Claims 4 and 9 stand rejected under 35 U.S.C. § 112, 2nd paragraph, as being indefinite in that dependency of the claims are inappropriate. Claims 4 and 9 have been amended to correct the dependency of the claims. Applicants respectfully request that the rejection of claims 4 and 9 as being indefinite be reconsidered and withdrawn.

III. Rejections under 35 U.S.C. § 102(a)

Claims 1, 2, 4-7 and 9-17 stand rejected as being anticipated by Agata et al., "*NM-3, a Novel Angiogenesis Inhibitor, Potentiates Dexamaethasone-Induced Apopotsis in Multiple Myeloma Cells*," Proceedings of the 2001 AACR-NCI-EORTC International Conference, p67 October 2001 (IDS reference C9). Filed concomitantly with this response is a declaration under 37 CFR § 1.132 as provided by *In re Katz*, 215 USPQ 14 (CCPA 1982), to remove this publication as a reference under 35 U.S.C. § 102(a). In light if this declaration, Applicants respectfully request that the rejections of claims 1, 2, 4-7 and 9-17 as being anticipated by Agata et al. be reconsidered and withdrawn.

IV. Rejections under 35 U.S.C. § 103(a)

Claims 1, 2, 4-7 and 9-20 stand rejected as being obvious over Agata et al., in view of DiPiro et al. These rejections are predicated on the availability of Agata et al as prior art. In light of the declaration under 37 CFR § 1.132 as provided by *In re Katz*, 215 USPQ 14 (CCPA 1982), to remove this publication as a reference, Applicants respectfully request that the rejections of claims 1, 2, 4-7 and 9-20 as being obvious over Agata et al., in view of DiPiro et al., be reconsidered and withdrawn.

V. Conclusion

In light of the foregoing, Applicants respectfully submit that the claims are in condition for allowance, and an early notification to that effect is earnestly solicited.

Should Examiner Jones have any questions regarding this response, a telephone call to the undersigned is invited. Please date stamp the enclosed postcard as evidence of receipt.

Respectfully submitted

Stephen J. Moloney
Reg. No. 44,947
Attorney for Applicant

ILEX Oncology Inc.
4545 Horizon Hill Blvd.
San Antonio, TX 78229-2263
(210) 949-8273

Date: 8/12/2004